CombinatoRx To Present At The Canaccord Adams Diabetes & Obesity Conference

Main Category: Diabetes
Also Included In: Obesity / Weight Loss / Fitness;  Conferences
Article Date: 02 Jun 2008 - 15:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

CombinatoRx, Incorporated (NASDAQ: CRXX) announced that John Randle PhD, Senior Vice President, Commercial Development is scheduled to present at the upcoming Canaccord Adams Diabetes & Obesity Conference at The Nikko Hotel in San Francisco. Mr. Randle is scheduled to present on Friday, June 6, 2008 at 10:20 am PST. Interested parties may access a live webcast of the presentation by visiting the CombinatoRx website at http://www.combinatorx.com.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a trial results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx please visit http://www.combinatorx.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its product candidates and their clinical potential, its plans for clinical and preclinical development of its product candidates, its business plans and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candidates, risks associated with the preclinical development of its product candidates, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

© 2008 CombinatoRx, Incorporated. All rights reserved.

CombinatoRx